

91. Dai J, Almazan T, Kim Y, Khodadoust M. Pembrolizumab in systemic and cutaneous T-cell lymphoma. *Ann Lymphomad*. 2018;2:3.
92. Wong HK, Wilson AJ, Gibson HM, et al. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides—cutaneous T cell lymphoma. *J Invest Dermatol*. 2006;126:212-219.
93. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. *J Clin Oncol*. 2016;34:2698-2704.
94. Khodadoust M, Rook AH, Porcu P, et al. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sézary syndrome: clinical efficacy in a Citn multicenter phase 2 study. *Blood*. 2016;128:181.
95. Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. *J Clin Oncol*. 2020;38:20-28.
96. Bar-Sela G, Bergman R. Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma. *JAAD Case Rep*. 2015;1:99-100.
97. Sekulic A, Liang WS, Tembe W, et al. Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion. *Mol Genet Genomic Med*. 2015;3:130-136.
98. Kohlmeyer J, Steimle-Grauer SA, Hein R. Cutaneous sarcomas. *J Dtsch Dermatol Ges*. 2017;15:630-648.
99. Toulmonde M, Penel N, Adam J, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. *JAMA Oncol*. 2018;4:93-97.
100. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol*. 2017;18:1493-1501.
101. Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful treatment of HIV-associated Kaposi sarcoma with immune checkpoint blockade. *Cancer Immunol Res*. 2018;6:1129-1135.
102. Saller J, Walko CM, Millis SZ, Henderson-Jackson E, Makanji R, Brohl AS. Response to checkpoint inhibitor therapy in advanced classic kaposi sarcoma: a case report and immunogenomic study. *J Natl Compr Canc Netw*. 2018;16:797-800.
103. Delyon J, Bizot A, Battistella M, Madelaine I, Vercellino L, Lebbe C. PD-1 blockade with nivolumab in endemic Kaposi sarcoma. *Ann Oncol*. 2018;29:1067-1069.
104. Hamacher R, Kämpfe D, Ahrens M, et al. 1506PPD-L1 inhibition — a new therapeutic opportunity in cutaneous angiosarcoma? *Ann Oncol*. 2017;28(suppl 5).
105. Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. *J Immunother Cancer*. 2017;5:58.
106. Martinez SR, Barr KL, Canter RJ. Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. *Arch Dermatol*. 2011;147:1058-1062.
107. Kandl TJ, Sagiv O, Curry JL, et al. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. *Oncoimmunology*. 2018;7:e1475874.
108. Domingo-Musibay E, Murugan P, Giubellino A, et al. Near complete response to pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. *J Immunother Cancer*. 2018;6:58.
109. Kodali S, Tipirneni E, Gibson PC, Cook D, Verschraegen C, Lane KA. Carboplatin and pembrolizumab chemoimmunotherapy achieves remission in recurrent, metastatic sebaceous carcinoma. *Ophthalmic Plast Reconstr Surg*. 2018;34:e149-e151.
110. Hamid O, Molinero L, Bolen CR, et al. Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: results from a phase I trial of atezolizumab. *Clin Cancer Res*. 2019;25:6061-6072.
111. Keilholz U, Mehnert JM, Bauer S, et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. *J Immunother Cancer*. 2019;7:12.
112. Choi FD, Kraus CN, Elsensohn AN, et al. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: a systematic review. *J Am Acad Dermatol*. 2020;82:440-459.

Answers to CME examination

Identification No. JA1120

November 2020 issue of the Journal of the American Academy of Dermatology.

Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME. *J Am Acad Dermatol* 2020;83:1239-53.

1. d
2. e

3. e
4. b